Literature DB >> 31744026

Iron and zinc: Nutrients with potential for neurorestoration in premature infants with cerebral white matter injury.

Joseph J Volpe1,2.   

Abstract

Entities:  

Keywords:  Prematurity; iron; white matter injury; zinc

Mesh:

Substances:

Year:  2019        PMID: 31744026      PMCID: PMC7029313          DOI: 10.3233/NPM-190369

Source DB:  PubMed          Journal:  J Neonatal Perinatal Med        ISSN: 1878-4429


× No keyword cloud information.

Introduction

Cerebral white matter injury (WMI) is the principal neuropathological lesion in premature brain [1, 2]. WMI is present in more than 50% of very preterm and extremely preterm infants, [3, 4] and the lesion and its morphological consequences underlie most of the subsequent neurological deficits observed [2]. The central cellular target of the WMI is the pre-oligodendrocyte (pre-OL), the precursor of the mature myelin-producing OLs, and injury to the pre-OL in the premature brain is followed by its dysmaturation and subsequently hypomyelination. The pre-OL injury leads to a variety of other dysmaturational events involving cerebral cortex, axons, and a variety of other neural structures, as discussed elsewhere [5]. Because the failure of maturation of this cell occurs over the ensuing weeks and months, the possibility of interventions in the premature period and in early infancy that prevent or correct this maturational failure, i.e., “neurorestorative” interventions, have become the focus of considerable research. Such interventions have included a variety related to nutritional factors, including quality and source of milk, components of milk, breastfeeding, but recent experimental and clinical studies have renewed focus on two metals, iron and zinc. These two so-called “transition” metals are the most abundant metals in human brain, and recent work indicates that they are critical for differentiation of pre-OLs to mature myelin-producing OLs. Their potential as neurorestorative interventions in WMI is the focus of this Commentary.

Pre-OL injury/dysmaturation

Pre-OLs, the principal cellular target in WMI of the premature infant [1, 2] are generated from OL progenitors and are the principal phase of the OL lineage during the premature period. Pre-OLs account for 90% of the lineage during the peak period of WMI in premature infants. Even at term, pre-OLs account for 50% of the lineage in cerebral white matter, while approximately 50% of the lineage are the more differentiated “immature” OLs [6]. Mature, myelin-producing OLs do not develop in human cerebral white matter to an appreciable degree until post-term, i.e., in the weeks and months post-term. The pre-OL begins ensheathment of white matter axons at approximately 30 weeks’ gestation [7]. This process is critical for axonal differentiation [2] and, as a consequence, axonal function. The latter is the critical driving force for cerebral cortical development (see later), which evolves rapidly as an activity-dependent process during the third trimester of gestation. The pre-OL is a highly vulnerable cell, with particular susceptibility to such insults as hypoxia, ischemia, inflammation, which lead to death via excitotoxic and free radical mediated mechanisms in cerebral WMI [1]. Notably, however, in the premature infant with WMI, pre-OLs are replenished in the subacute period but fail to differentiate over the ensuing weeks/months to later phases of the OL lineage. Thus, as noted above, failure of pre-OL differentiation is the basis of the subsequent hypomyelination but, likely also, the neuronal-axonal dysmaturational disturbances that occur. Thus, factors that could enhance pre-OL differentiation and overcome the block in cerebral WMI would be of great restorative potential. As noted above, therein lies the focus on the two most abundant metals in human brain, iron and zinc, which now appear to be critical for pre-OL differentiation.

Iron and pre-OL maturation/myelination

Iron is the most abundant transition metal in brain, and the OL contains the highest concentrations of iron among brain cellular elements [8-10]. Experimental studies have shown that acquisition of iron by developing OLs is necessary for myelination and that perinatal iron deficiency results in impaired myelination [9, 11–14]. The particular importance of iron for OL development and myelination was illustrated by recent studies of a genetic model of mucolipidosis IV, a human disorder with impaired myelin development. The molecular deficit responsible for the disturbance was shown to involve a lysosomal ion channel necessary for iron uptake into developing OLs [15]. Iron is necessary for the function of numerous enzymes involved in OL differentiation and myelination [9]. Iron deficiency in human premature infants is a common phenomenon that is likely to be associated with impaired OL maturation and myelination. Although the data are not entirely consistent, most studies show impairments of motor, cognitive and behavioral development in iron-deficient infants [16-20]. Iron deficiency in the neonatal period is usually related to dietary deficiency, particularly in the context of breast-feeding and prematurity [13, 21, 22]. Indeed, as many as 10% of infants in the first two years of life in the United States and 15% of breast-fed Canadian infants exhibit iron deficiency. Because premature birth deprives the infant of the primary period of fetal iron deposition, i.e., the third trimester of gestation, the risks are still higher in such infants. Supportive of an effect on myelin development in iron-deficient infants is the finding on studies of auditory and visual evoked potentials of prolonged latencies, without impairment of amplitudes [23-26]. (The normal maturational decline in latencies relates to acquisition of myelin, whereas changes in amplitude relate more to neuronal development [27]). A recent study of delayed umbilical cord clamping (DCC) in full-term infants suggests a beneficial effect of iron on MRI-quantitated myelin at four months of age [28]. Thus, infants followed after DCC had 48% higher serum ferritin levels and myelin content at 4 months of age, when compared to infants who had immediate cord clamping. Moreover, because infants with higher iron stores at 4 months of age have been shown to persist with higher stores later, the findings suggest that the positive effect on myelination may persist [29]. More data are needed, but higher iron stores could represent an important neurorestorative goal in premature infants. A particular need to assess deficient iron in developing human brain in vivo is apparent. Recent work suggests that newly developed MRI methods, capitalizing on the potent effects of iron on magnetic properties of brain, could satisfy that need [9]. It now appears feasible for such advanced MRI methods to detect infants with deficient brain iron and thus to target such infants for iron therapy. Since premature infants with WMI exhibit impaired OL maturation, treatment of such infants with iron according to the quantitative levels of iron present in their white matter would seem possible and, perhaps, optimal. Such treatment would probably best be commenced after the acute/subacute period when exposures to insults (e.g., ischemia, etc.), that could lead to free radical production have ceased. This caveat relates to the capacity of intracellular free iron to lead to production of superoxide anion [2]. As these advanced MRI methods evolve further, in the interim careful attention to iron homeostasis and supplementation as needed in premature infants (beyond the acute/subacute period) could have neurorestorative potential. This notion demands further research

Zinc and pre-OL maturation/myelination

Following iron, zinc is the second most abundant metal in the brain and is obtained exclusively through dietary intake [30]. Experimental studies have shown that zinc is critical for a variety of aspects of brain development, including OL development [31-35]. The effect is mediated particularly by an OL-specific zinc finger protein (Zfp 488) that functions as a transcriptional co-regulator important for OL differentiation [36]. The recent development of synthetic fluorescent sensors has identified the pre-OL as the key cell involved in the role of zinc in oligodendroglial differentiation. Thus, utilizing such a sensor, Bourassa et al., [37] have shown recently that zinc concentrations in developing OLs are relatively high during differentiation and decline after maturation is achieved. These findings suggest that the zinc content of pre-OLs is important for their differentiation. Notably, as with iron, altered zinc balance is involved in experimental models of ischemic and excitoxic death [38-40]. Thus, exogenous zinc should probably be considered after the acute/subacute period when ischemic insults are no longer prevalent. The clinical relevance of this work on zinc and pre-OL differentiation remains to be clarified fully, but it is notable that preterm infants are vulnerable to zinc deficiency because of high zinc requirements, diminished zinc stores (most zinc stores are acquired in the last trimester of gestation), and suboptimal zinc absorption [41-43]. Moreover, zinc concentrations in human milk are highly variable, and current dietary guidelines for zinc intake for preterm infants are based on limited data [42, 44]. More data are needed in human preterm infants on OL maturation, myelination and neurological development, in relation to zinc status, and on ideal amounts of dietary zinc intake. Nevertheless, on balance, the data raise the real possibility that zinc intake (beyond the acute/subacute period) could have restorative potential for premature infants with WMI and its associated failure of pre-OL maturation. More data are clearly needed.

Conclusions

Recent advances in methodologies to study the status of iron and zinc have enabled insight into the critical roles these two most abundant metals play in developing brain. The data point to a critical role in pre-OL differentiation, impairment of which underlies the hypomyelination characteristic of premature infants with cerebral WMI. Premature infants have high requirements for these metals and have been deprived of the critical transplacental transfer in the third trimester. Careful attention to iron and zinc status in such infants and appropriate supplementation after the acute/subacute period could serve as important restorative interventions in infants with cerebral WMI.
  40 in total

1.  Association between iron status and neurodevelopmental outcomes among VLBW infants.

Authors:  Noriko Kon; Kyoko Tanaka; Mariko Sekigawa; Yoshie Negishi; Naomi Yoshikawa; Ken Hisata; Hiromichi Shoji; Toshiaki Shimizu
Journal:  Brain Dev       Date:  2010-04-24       Impact factor: 1.961

Review 2.  Zinc and copper requirements in preterm infants: an examination of the current literature.

Authors:  Ian J Griffin; Magnus Domellöf; Jatinder Bhatia; Diane M Anderson; Neelam Kler
Journal:  Early Hum Dev       Date:  2013-08-30       Impact factor: 2.079

3.  An oligodendrocyte-specific zinc-finger transcription regulator cooperates with Olig2 to promote oligodendrocyte differentiation.

Authors:  Shu-Zong Wang; Jennifer Dulin; Heng Wu; Edward Hurlock; Sang-Eun Lee; Kyle Jansson; Q Richard Lu
Journal:  Development       Date:  2006-09       Impact factor: 6.868

4.  Effects of iron supplementation of LBW infants on cognition and behavior at 3 years.

Authors:  Staffan K Berglund; Björn Westrup; Bruno Hägglöf; Olle Hernell; Magnus Domellöf
Journal:  Pediatrics       Date:  2012-12-10       Impact factor: 7.124

Review 5.  Zinc homeostasis and zinc signaling in white matter development and injury.

Authors:  Christopher M Elitt; Christoph J Fahrni; Paul A Rosenberg
Journal:  Neurosci Lett       Date:  2019-05-04       Impact factor: 3.046

6.  Latent iron deficiency in utero is associated with abnormal auditory neural myelination in ≥ 35 weeks gestational age infants.

Authors:  Sanjiv B Amin; Mark Orlando; Hongyue Wang
Journal:  J Pediatr       Date:  2013-08-09       Impact factor: 4.406

Review 7.  Zinc deficiency in infants and children: a review of its complex and synergistic interactions.

Authors:  Nancy F Krebs; Leland V Miller; K Michael Hambidge
Journal:  Paediatr Int Child Health       Date:  2014-09-09       Impact factor: 1.990

Review 8.  Zinc and infant nutrition.

Authors:  M Leigh Ackland; Agnes A Michalczyk
Journal:  Arch Biochem Biophys       Date:  2016-06-15       Impact factor: 4.013

9.  Impaired myelination and reduced brain ferric iron in the mouse model of mucolipidosis IV.

Authors:  Yulia Grishchuk; Karina A Peña; Jessica Coblentz; Victoria E King; Daniel M Humphrey; Shirley L Wang; Kirill I Kiselyov; Susan A Slaugenhaupt
Journal:  Dis Model Mech       Date:  2015-09-17       Impact factor: 5.758

10.  Effects of Delayed Cord Clamping on 4-Month Ferritin Levels, Brain Myelin Content, and Neurodevelopment: A Randomized Controlled Trial.

Authors:  Judith S Mercer; Debra A Erickson-Owens; Sean C L Deoni; Douglas C Dean; Jennifer Collins; Ashley B Parker; Meijia Wang; Sarah Joelson; Emily N Mercer; James F Padbury
Journal:  J Pediatr       Date:  2018-07-06       Impact factor: 6.314

View more
  3 in total

Review 1.  Minerals in Pregnancy and Their Impact on Child Growth and Development.

Authors:  Patricia Miranda Farias; Gabriela Marcelino; Lidiani Figueiredo Santana; Eliane Borges de Almeida; Rita de Cássia Avellaneda Guimarães; Arnildo Pott; Priscila Aiko Hiane; Karine de Cássia Freitas
Journal:  Molecules       Date:  2020-11-30       Impact factor: 4.411

2.  Artificial Intelligence-Based MRI in Diagnosis of Injury of Cranial Nerves of Premature Infant and Its Correlation with Inflammation of Placenta.

Authors:  Gui Liao
Journal:  Contrast Media Mol Imaging       Date:  2022-03-27       Impact factor: 3.161

3.  Evaluation of Essential and Toxic Elements in the Blood of 0-14-Year-Old Children in Hunan, China From 2013 to 2019: A Retrospective Analysis.

Authors:  Shan Tan; Yang Yang; Zhiheng Chen; Lingling Zhao; Zuocheng Yang; Hongmei Dai; Wei He; Mei Jiang; Yanhua Yao; Ke Huang; Liu Li; Pengfei Zhu; Shasha Xu; Mingyi Zhao; Minghua Yang
Journal:  Front Public Health       Date:  2022-04-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.